The impact of individual Cognitive Stimulation Therapy (iCST) on cognition, quality of life, caregiver health, and family relationships in dementia

Orrell, Martin; Yates, Lauren; Leung, Phuong; Kang, Sujin; Hoare, Zoe; Whitaker, Christopher; Burns, Alistair; Knapp, Martin; Leroi, Iracema; Moniz-Cook, Esme; Pearson, Stephen; Simpson, Stephen; Spector, Aimee; Roberts, Stephen; Russell, Ian; de Waal, Hugo; Woods, Robert; Orgeta, Vasiliki

PLoS Medicine

DOI:
10.1371/journal.pmed.1002269

Published: 28/03/2017

Peer reviewed version

Dyfniad o’r fersiwn a gyhoeddwyd / Citation for published version (APA):

Hawliau Cyffredinol / General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
The impact of individual Cognitive Stimulation Therapy (iCST) on cognition, quality of life, caregiver health, and family relationships in dementia: a randomized controlled trial

Martin Orrell PhD¹, Lauren Yates PhD¹, Phuong Leung MSc², Sujin Kang MSc³, Zoe Hoare PhD³, Chris Whitaker MSc⁴, Alistair Burns MD⁵, Martin Knapp PhD⁶, Iracema Leroi MD⁵, Esme Moniz-Cook PhD⁷, Stephen Pearson MD⁸, Stephen Simpson MD⁹, Aimee Spector PhD¹⁰, Steven Roberts (BSc, Hons)¹¹, Ian Russell PhD¹², Hugo de Waal MD¹³,¹⁴, Robert T Woods MSc¹⁵, Vasiliki Orgeta PhD²

¹ Institute of Mental Health, University of Nottingham, Nottingham, UK
² Division of Psychiatry, University College London (UCL), London, UK
³ North Wales Organisation for Randomised Trials in Health (& Social Care), University of Bangor, Bangor, UK
⁴ Whitaker Research Ltd., Bangor, UK
⁵ Institute of Brain, Behaviour and Mental Health, Manchester Academic Health Sciences Centre, Manchester, UK
⁶ Personal Social Services Research Unit, London School of Economics and Political Science, London, UK
⁷ Faculty of Health and Social Care, University of Hull, Hull, UK
⁸ Devon Partnership NHS Trust, Devon, UK
⁹ Dorset Healthcare University NHS Foundation Trust, Dorset, UK
¹⁰ Research Department of Clinical, Educational and Health Psychology, University College London, London, UK
Correspondence to: Professor Martin Orrell

Address: Institute of Mental Health, University of Nottingham Innovation Park Jubilee Campus, Triumph Road, Nottingham, NG7 2TU.
m.orrell@nottingham.ac.uk

Word count: 6139
Abstract

Background Cognitive Stimulation Therapy (CST) is a well-established group psychosocial intervention for people with dementia. There is evidence that home-based programmes of cognitive stimulation delivered by family caregivers may benefit both the person and the caregiver. However, no previous studies have evaluated caregiver-delivered CST. This study aimed to evaluate the effectiveness of a home-based, caregiver-led individual Cognitive Stimulation Therapy (iCST) program in (i) improving cognition and quality of life (QoL) for the person with dementia and (ii) mental and physical health (wellbeing) for the caregiver.

Methods and Findings

A single-blind, pragmatic randomized trial (RCT) at eight study sites across the UK. The intervention and blinded assessment of outcomes were conducted in participants’ homes. 356 people with mild to moderate dementia and their caregivers recruited from memory services, and community mental health teams. Participants were randomly assigned to iCST (75, 30 minute sessions) or treatment as usual (TAU) control over 25 weeks. iCST sessions consisted of themed activities designed to be mentally stimulating and enjoyable. Caregivers delivering iCST received training and support from an unblind researcher.

Primary outcomes were cognition (Alzheimer’s Disease Assessment Scale – cognitive [ADAS-Cog]) and self-reported quality of life (QoL) (Quality of Life Alzheimer’s Disease [QoL-AD]) for the person with dementia, and general health status (Short Form-12 [SF-12]) for the caregiver. Secondary outcomes included: quality of the caregiving relationship from the perspectives of the person and of the caregiver (Quality of the Carer Patient Relationships Scale), and health-related QoL (EQ5D) for the caregiver.
Intention to treat (ITT) analyses were conducted. At the post-test (26 weeks), there were no differences between the iCST and TAU groups in the outcomes of cognition (MD = -0.55, 95% CI -2.00 to 0.90; p=0.45), and self-reported quality of life (QoL) (MD = -0.02, 95% CI -1.22 to 0.82; p= 0.97) for people with dementia, or caregivers’ general health status (MD=0.13, 95% CI -1.65 to 1.91; p=0.89). However, people with dementia receiving iCST rated the relationship with their caregiver more positively (MD = 1.77, 95% CI 0.26 to 3.28; p=0.02) and iCST improved QoL for caregivers (EQ-5D, MD = 0.06, 95% CI 0.02 to 0.10; p=0.01). Forty percent (72/180) of dyads allocated to iCST completed at least two sessions per week, with 22% (39/180) completing no sessions at all. Study limitations include low adherence to the intervention.

Conclusions
There was no evidence that iCST has an effect on cognition or QoL for people with dementia. However, participating in iCST appeared to enhance the quality of the caregiving relationship and caregivers’ QoL.

Trial registration
The iCST trial is registered with the ISRCTN registry (identified ISRCTN 65945963, URL: DOI 10.1186/ISRCTN65945963).

Why was this study done?

- Cognitive Stimulation Therapy (CST) is a structured group activity programme for people with dementia, which has been shown to improve quality of life and cognition.

- This therapy is recommended by organisations such as the Alzheimer’s Disease International and the UK National Institute for Health and Care Excellence.
• Although CST is becoming more widely available both in the UK and internationally, some people may not have access to groups because groups are not available near their home, they are not able to get to centers offering groups because of transport, health or mobility problems, or they would prefer not to do group activities.

• This study aimed to look at the potential use and benefits of an adapted version of CST called individual CST (iCST) delivered by a family carer or friend at the person with dementia’s home for 30 minutes ideally two or three times a week.

What did the researchers do and find?

• The research team produced the iCST programme (including a manual, activity workbook, and materials such as maps and dominoes) in collaboration with people with dementia, carers, healthcare professionals, and experts.

• A randomized controlled trial (RCT) involving 356 pairs of people with dementia and carers was carried out to test whether iCST benefits cognition and quality of life for people with dementia, and mental and physical health for carers.

• Participants were randomly split between two groups; 180 pairs received iCST, and 176 pairs continued with activities, treatments, and services offered as part of usual care, but they did not receive iCST.

• The study found that people with dementia receiving iCST did not benefit in terms of cognition or quality of life, neither was there evidence to suggest iCST improved carers’ mental or physical health. However, people with dementia in the
iCST group reported better relationship quality with their family carer at 26 weeks, and carers delivering iCST had better quality of life at 26 weeks.

What do these findings mean?

- We did not find that iCST improves cognition or quality of life for people with dementia.

- Given iCST appears to have a positive effect on the caregiving relationship and carer wellbeing, the programme might be a useful part of personally tailored home care packages.

- More research is needed to fully understand the impact of carer-led CST-based therapies for people with dementia.
Introduction
There are an estimated 5.3 million individuals with dementia in the United States with the number of cases rising each year as the population ages.\[1\] Family caregivers are an essential source of care with an estimated economic value of $217 billion a year.\[2\]

Dementia caregiving poses unique challenges, and whilst there may be positive aspects, often this role is stressful and can adversely affect the physical and mental health of the caregiver.\[3,4\] The stress-health model indicates the experience of psychological, behavioral, and physical symptoms associated with dementia are stressful and can reduce quality of life (QoL) for the person and their caregiver. \[4-6\] In addition, the person’s increasing dependence on others to fulfill basic needs, restructuring of the established relationship, and apathy can all reduce the quality of the relationship between the caregiver and recipient.\[7-9\] Conflict in the caregiving relationship is a risk factor for deterioration of functioning in the person with dementia, and presentation to services;\[10\] and there is evidence to suggest that maintenance of this relationship may facilitate a good quality of life, slow the progression of cognitive and functional decline, and delay institutionalization.\[11,12\]

There is growing recognition that psychological interventions can improve quality of life, and should be more widely available. Amongst those which enhance the quality of life of people with dementia, Cognitive Stimulation Therapy (CST) has a robust evidence base, \[13-15\] and has been shown to improve patient QoL and cognition, and also to be cost-effective.\[16\] An extended programme of maintenance CST (CST plus an additional 24 weekly sessions) was found to improve QoL.\[17\]
Cognitive stimulation is based on the theory of ‘use it or lose it’ whereby mental stimulation may counter or slow cognitive decline and evidence that activation of neurons may enhance neuronal function and survival.[18,19] CST sessions are designed to provide general stimulation of a range of cognitive skills through enjoyable activities in a social setting, though language appears to be particularly affected.[20] Further investigation of CST’s impact on QoL indicate that the domains of energy level, memory, ability to do chores, and relationship with caregiver are most responsive to improvement, and that improvements in QoL may be mediated by improvements in cognition.[21] Typically, CST is delivered in day centers or residential care facilities, without the family caregiver. The stress-health model suggests that improvements in quality of life and cognition from CST may improve caregiver outcomes, but few studies have examined this.[5]

Many of the therapies currently available are directed at either caregivers or people with dementia but a meta-analysis of psychological interventions for caregivers suggests that interventions are less efficacious when they target caregivers alone.[22] Home based, multi-component dyadic interventions, engaging both the caregiver and the person with dementia have been found to yield a range of benefits including; reduction in behavioral symptoms;[23] reduction in negative caregiver reactions;[24] and reduction in nursing home admissions.[25] The current evidence on both caregiver-focused and dyadic interventions also suggests that delivery one to one is more effective than in a group.[6,22]

This suggests that a home-based, one-to-one version of CST led by a family caregiver may yield benefits for both the person and the caregiver. Few studies have
focused on the use of cognitive stimulation based programmes delivered in the home, and CST has never been directly adapted for use in this context. However, a small study of home-based memory management by family caregivers with psychoeducation improved memory in the person with dementia, improved caregiver well-being, and reduced care home admissions by 18 months follow-up.[26] Similar benefits in cognition in people with dementia and caregiver well-being have been reported in other studies.[27,28] A further potential benefit of developing a home-based version of CST would be increasing the accessibility of the intervention for people unable to get to groups due to health/mobility problems, or lack of groups in the local area, or those who would prefer not to participate in group activities.[29]

The aim of the iCST trial was to investigate the primary outcomes of whether family caregiver-delivered CST improves (a) cognition and QoL of people with dementia, and (b) mental and physical health of caregivers. We hypothesized iCST may elicit cognitive benefits for the following reasons; (i) the programme provides mental stimulation through multi-sensory activities exercising a range of cognitive skills (e.g. memory, communication) in an environment that supports learning;[30] (ii) like CST, iCST focuses on implicit memory which tends to be maintained longer than explicit memory and, moreover, responds to stimulation;[31] (iii) discussion of new thoughts and ideas, and making associations (key principle of iCST) stimulates language.[30] The existing evidence on group CST and other individual family-led cognitive interventions, [13,26-28] also supports the choice of cognitive change as a primary outcome in this trial. QoL was also chosen as a primary outcome because; (i) improvements in cognitive function appear to mediate improvements in QoL therefore if iCST benefitted people cognitively as predicted, we expected to observe
an associated positive impact on QoL and (ii) cognitive stimulation has consistently been found to improve QoL.[15]

Secondary outcomes for people with dementia included: behavioural and psychological symptoms, activities of daily living, depressive symptoms, and the quality of the caregiving relationship. We posited that iCST may improve the caregiving relationship because (i) improving cognition may help people communicate more effectively with their caregiver which is associated with higher relationship satisfaction;[11] and (ii) the programme provides an opportunity for people and their caregivers to participate in enjoyable activities together.[32,33] In addition, enhancing the quality of the caregiving relationship may also improve QoL for the person with dementia,[11] supporting selection of QoL as a primary outcome in this trial.

For caregivers, health related quality of life (QoL), mood symptoms, resilience, and relationship quality were secondary outcomes. We hypothesized that participating in activities together may help caregivers develop or maintain a closer relationship with the person they are caring for, and focusing these kinds of positive aspects of caregiving may improve wellbeing and reduce stress and burden.[34] Experience of enjoyment through caregiving could serve as a coping resource, therefore we anticipated participating in iCST may positively impact resilience.[34]
Methods

Ethics statement

Ethical approval was obtained through the East London 3 Research Ethics Committee (ref no. 10/H0701/71). The study was registered as a clinical trial (ISRCTN 65945963). Participants gave informed consent in accordance with the UK Mental Capacity Act (2005).

Trial design and setting

We conducted a single-blind, two-group pragmatic randomized trial of iCST over 25 weeks against TAU over 25 weeks (Fig 1). The full protocol is described elsewhere.[29] The trial operated from eight centers across the UK (London, Bangor, Dorset, Devon, Hull, Lincolnshire, Manchester, and Norfolk & Suffolk). From April 2012 to July 2013 recruitment took place in a variety of community settings including NHS memory clinics, community mental health teams for older people (CMHTs), and associated outpatient clinics.

Recruitment

Participants were recruited in the community from memory clinics, community mental health teams (CMHTs), outpatient clinics, day centres, and voluntary organizations such as the Alzheimer’s Society. The aim of the project was briefly described to potential participants by members of the research and clinical team, and permission for them to be contacted by local researchers was obtained prior to further contact. Research assistants discussed the project and provided full details to participants,
answered any questions related to the project and, if participants agreed, undertook written informed consent.

Participants

Participants met the criteria for dementia of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), had dementia of mild to moderate severity (Mini-Mental State Examination [MMSE] score ≥ 10), had some ability to communicate and understand, and were able to see and hear well enough to participate in activities. In addition, each participant lived in the community, had no major illness affecting their participation, and had a caregiver (relative or friend) able to deliver the intervention and act as an informant for the assessments. If caregivers were not able to support the person in the delivery of iCST sessions they were not recruited into the trial.

Sample size

Based on previous studies and the Cochrane Review of cognitive stimulation, we conservatively powered the trial to detect a mean difference (MD) between iCST and TAU of 0.35 on the ADAS-Cog. To yield 80% power when using a t-test with a two-sided 5% significance level, and assuming 15% attrition, we needed a sample size of 306 dyads. As actual attrition was 23% (83/356), we more than compensated by increasing the target to 356 dyads during the trial. One-hundred-and-eighty dyads were allocated to iCST, and 176 received TAU.
Randomization and blinding

After baseline assessment we allocated dyads (people with dementia and caregivers) at random between iCST and TAU groups in the ratio 1:1. To prevent subversion, we used dynamic allocation [39] and the web-based randomization service managed by North Wales Organisation for Randomised Trials in Health (NWORTH), an accredited UK Clinical Trials Unit. We stratified participants by center and use of cholinesterase inhibitors. We concealed allocations from researchers conducting 13 week mid-point and post-test (26 weeks) assessments. To assess the success of blinding, these researchers recorded the perceived allocation of each participant at each assessment.

Intervention

The iCST program was delivered at home by a caregiver in regular contact with the person with dementia (see Text A in S1 Appendix). The iCST package included: a manual containing guidance on sessions, key principles of iCST, and ideas for activities; an activity workbook with paper resources for activities; and a toolkit of additional items such as playing cards, dominoes, sound activity compact discs (CDs), and maps. Dyads engaged in up to three, 30-minute sessions of structured cognitive stimulation through themed activities (e.g. word games, current affairs, being creative, see Table A in S1 Appendix for all iCST themes) per week over 25 weeks (maximum of 75 sessions). A sample session is shown in Box 1 with details of the procedure and content of the first session of the iCST program: ‘My Life (Life History) Part I’. All sessions follow the same general structure, and a selection of activities is offered for each theme with two levels of difficulty; Level A activities were
intended to be less cognitively demanding and more discussion based, whilst Level B activities were more cognitively challenging (see Box 1 for examples).

**Box 1. Sample iCST session: My Life (Life History) Part I**

**Introduction / warm-up (5-10 minutes)**
- Discuss orientation information such as the day, date, weather using aids such as the newspaper, and surroundings (e.g., looking out of the window to prompt comments about the weather). The purpose of this introduction is to orientate the person to the here and now.
- Talk about something currently happening; this could be national or local news, events in the community, or personal events such as birthdays and special occasions (e.g., birth of a new child in the family). Discussion can be prompted using newspapers, online news articles, documents such as invitations etc.

**Main activity (20-25 minutes)**
- **Level A:** Look at old and recent family photographs of family and friends. Prompt with questions about shared traits of family members, interesting stories about them, tips to maintain good relationships or advice you would give about having a family.
- **Level B:** Record family history in a family tree. Add details for each generation such as relationships, birthdays, and place of birth. Share stories about the family and talk about how people’s lives have changed over the years.

**Materials from iCST activity workbook:** An example of a family tree and a template to give dyads a starting point for this activity, which can be used for the Level B option. No materials are provided for Level A as this requires dyads to provide photographs from their own personal collection.

**Materials from the iCST toolkit:** The color pencils could be used to design the family tree, the UK and world maps could be used to prompt discussion about places of birth and location of family members, and the magnifying card could be used to see finer details on photographs, or written records such as birth certificates which may be used as cues in the activity.

The development of the programme was rigorous, adhering to the UK Medical Research Council (MRC) framework.[40] The program was based on a modified CST manual, the recent Cochrane review of cognitive stimulation,[15] an individual manualized programme of reality orientation (RO)[28] and consultation with caregivers, people with dementia and professionals in dementia care in a series of focus groups, consensus work, and field testing.[41] The iCST package included: a manual containing guidance on sessions, key principles of iCST, and ideas for activities; an activity workbook with paper resources for activities; and a toolkit of
additional items such as playing cards, dominoes, sound activity compact discs (CDs), and maps.

*Treatment adherence, caregiver training, and support*

We followed previous studies [42] applying the treatment integrity model, developed and expanded on by Lichstein, Riedel and Grieve.[43] Intervention pairs were visited at home by a dementia researcher as soon as possible after randomization to provide them with the iCST materials and train them in the iCST approach. Dementia researchers included mental health nurses, clinical psychologists, occupational therapists, and research assistants. All researchers who provided support to family caregivers received standardized training and followed a treatment protocol. The standardized training package researchers delivered to caregivers taught them how to: use the iCST manual and activity workbook and implement the key principles of iCST. Clips from the group CST training DVD, ‘Making a Difference 2’,[44] were shown to demonstrate good practice. After learning about the iCST approach, the caregiver delivered the first session with support from the researcher, who provided assistance and feedback. Typically training visits lasted between 60 and 90 minutes. Caregivers also received up to ten hours of support from the dementia researcher during the trial, including telephone support (initially weekly), and two scheduled monitoring home visits (monitoring visit 1 [MV1] and monitoring visit 2 [MV2]). If the key family caregiver was unable to continue delivering iCST, an appropriate caregiver was substituted if possible.
Treatment as usual (TAU)

As the trial examined the effects of adding iCST to TAU, the regular services offered were the same in both groups. Not surprisingly TAU varied between and within centers, and over time (see Text B in S1 Appendix for more information). Standard best practice methods around pragmatic RCTs were followed and it was expected that both the iCST and TAU groups had access to a similar range and similar types of mentally stimulating activities outside the research trial, for instance non CST-based group activities offered by day centers, hobbies, gardening, support groups, or visits to places of interest. In terms of use of CST, participants who had attended CST groups in the three months before recruitment into the trial were considered ineligible. Sites were asked to record any instances of engagement in CST or other activities offered by local services during the trial. As far as we were aware, participants were unlikely to have access to any comparable individual cognitive stimulation interventions, as this type of structured therapy is generally not available in the UK. General service use and medication were recorded in both groups.

Assessment and measures

We completed primary and secondary measures at baseline (BL), 13 weeks after baseline (mid-point), and 26 weeks after baseline (post-test – primary endpoint).

Outcome measures for the person with dementia

The ADAS-Cog was selected to measure the primary outcome of cognition and consists of 11 tasks assessing memory, language, praxis, attention, and other cognitive abilities.[38] The scale is widely used and psychometrically sound, with good reliability and validity. The measure we selected to assess QoL was the Quality
of Life Alzheimer’s Disease Scale (QoL-AD), which has good validity and reliability.[45] Secondary outcomes included: dementia-specific QoL (Dementia Quality of Life, DEMQOL),[46] neuropsychiatric symptoms (Neuropsychiatric Inventory, NPI),[47] functional ability (Bristol Activities of Daily Living Scale, BADLS),[48] and depressive symptoms (Geriatric Depression Scale, GDS-15).[49]

Quality of the carer-patient relationship (Quality of the Carer-Patient Relationship Scale, QCPR) was an additional measure included in response to data from the field-testing phase of the trial, which indicated that the caregiving relationship may benefit as a result of participating in the intervention.[50,51] The QCPR is split into two subscales; criticism and warmth. As a covariate, we graded severity of dementia using the Clinical Dementia Rating Scale (CDR).[52]

**Outcome measures for the caregiver**

The primary outcome for caregivers was mental and physical health (wellbeing) measured by the Short Form-12 Health Survey (SF-12).[53] Secondary outcomes were: anxiety and depressive symptoms (Hospital Anxiety and Depression Scale, HADS),[54] health-related quality of life (EQ-5D)[55] to which we applied societal weights,[56] resilience (Resilience Scale, RS-14),[57] and quality of the caregiving relationship (QCPR).[50]

**Caregiver adherence measures**

Caregivers in the iCST group completed self-report questionnaires at the set-up visit, MV1 and MV2, which required them to rate their confidence (4-point scale: very little, fair, good, very confident) in delivering iCST, quality of support (5-point scale A:
excellent, very good, good, fair, poor), knowledge of iCST (see 5-point scale A), successful engagement (5-point scale B: all of the time, most of the time, some of the time, a little of the time, none of the time), and application of specific techniques (opinions rather than facts, developing ideas in a sensitive manner, incorporating person’s interests into programme, adapting sessions for the person) and skills in delivering the sessions (see 5-point scale B). The questionnaire was developed specifically for use in this trial, to measure treatment integrity, and whether the intervention was carried out as intended.[58]

Anticipated risks

As there are no documented harmful side effects from participating in CST, we expected few adverse events in this trial.[13] Sites recorded and reported Serious Adverse Events (SAEs) to the Chief Investigator (CI).

Statistical Analysis

We analyzed all available data by treatment allocated, following the principles of Intention to Treat (ITT). Statisticians performing the main analysis were blind to randomized intervention assignment. We used analysis of covariance (ANCOVA) to estimate the differences between iCST and TAU groups for people with dementia in primary and secondary outcomes at 13 week mid-point and post-test (26 weeks). The model adjusted for covariates expected to influence outcome variables including baseline score on the outcome measures, and the age of the person with dementia, and relationship with the caregiver. The fixed factors were gender, marital status and use of anti-cholinesterase inhibitors; and center was a random factor. We used a similar ANCOVA for primary and secondary outcomes for caregivers at 13 week mid-
point and post-test with covariates of baseline scores, age of caregiver, and relationship with the person with dementia, fixed factors of gender and marital status, and random factor of center. Effect sizes were calculated using Cohen’s d.

Adherence analyses
Carer adherence data were collected and paired t test analysis performed to compare the differences between the set-up visit, MV1, and MV2.

Exploratory analyses
To analyze adherence, linear regression was used to assess the relationship between the follow-up outcome measures and the number of iCST sessions attended after adjusting for baseline outcome measures. This method was considered more efficient for an exploratory analysis than either defining an average number of sessions to complete a week or pre-defining a number of sessions to be ‘enough’ of the therapy.

Any participants who did not provide any data post-test or at the 13 week mid-point were not included in the analysis. If a participant had less than 20% of the items missing for a scale then we pro-rated the scores for that measure.[59] This left fewer than ten total scores missing and for these we then used multiple imputation based on a linear regression method. The number of imputations created was based on the percentage of missing data.

Results
Preliminary analyses
There were no differences between the two groups at baseline on clinical and demographic factors (Table 1). Three hundred and fifty six pairs participated in the trial. Recruitment was complete by July 2013, with the final post-test assessments complete by February 2014. Analysis by treatment allocated included 134 iCST, and 139 TAU dyads. Twenty-three percent (83/356) of the total sample (75/356, 21% excluding deaths) dropped out by post-test. Rates of attrition in the iCST (46/180, 26%) and TAU (37/176, 21%) groups were not significantly different. Average baseline MMSE scores were similar (iCST=21·12, SD=4·48; TAU=21·33, SD=4·11). Characteristics of completers and non-completers are provided in Table B in S1 Appendix, which shows no differences at baseline. Reasons for drop outs are shown in Table C in S1 Appendix. Out of the 46 withdrawals in the iCST group, 18 did not wish to continue (sometimes noting they were too busy) and 28 were unable to participate largely through ill health or having relocated. Six from the TAU group withdrew because they were not allocated to iCST, amounting to only one in 30 TAU participants. Seventy percent of the sample had mild dementia (CDR score = 1). In relation to other activities, there was no difference between the intervention and TAU groups at baseline or post-test in terms of day center attendance, lunch club attendance, or education classes.

*Researcher ratings of perceived group allocation*

The response rate for the researcher perceived group allocation questionnaires (see Table D and Table E in S1 Appendix) was high at the 13 week mid-point (92%, 264/288) and post-test (93%, 255/273). At both assessment time points, most blinded researchers were not able to identify whether dyads were receiving iCST or TAU (60%, 160/264 at mid-point and 57%, 145/255 post-test). Overall, again at both
time points, only 23% were able to accurately predict which group the dyads had been allocated to, with the remainder judging incorrectly.

**Outcomes for person with dementia**

The primary outcomes of cognition and quality of life (ADAS-Cog, QoL-AD) were not statistically significant at the 5% level between iCST group and TAU group at 13 week mid-point, or the primary end point post-test (Table 2). However, there was a significant improvement in QCPR total score for the iCST group relative to the TAU group, with a mean difference of 1·77 (95% CI from 0·26 to 3·28; \(p=0.02\)), effect size of 0.32. No significant differences between groups were detected for activities of daily living, depression or behavioral and psychological symptoms. There were no differences in primary or secondary outcomes at 13 week mid-point (Table 3). Summaries of outcomes and change from baseline scores are provided in Table F and table G in S1 Appendix respectively.

**Caregiver outcomes**

There were no differences in the primary outcome of functional health status (wellbeing) on the SF-12 (Table 2). The EQ-5D calculated utility value for the caregiver was significantly better post-test for the iCST group, with a mean difference of 0·06 (95% CI 0·01 to 0·10, \(p=0.014\)), effect size of 0.25. Reduced HADS depression score in the iCST group at post-test (-0·51, 95% CI -1.09 to 0.08, \(p=0.09\)) did not reach significance. No differences in any other outcomes were found at 13 week mid-point (Table 3).

**Adherence analysis**
One hundred and seventy-three carers completed questionnaires at set-up, 141 at MV1, and 124 at MV2. Some carers did not complete the questionnaires as they dropped out before the monitoring visit. At the set up visit carers scored their knowledge of iCST at 3.14 (out of 4), and it had improved to 3.58 at MV2 (MD=0.371, 95% CI 0.285 to 0.457, \( p \leq 0.001 \)). In addition, carers confidence in delivering iCST improved from 2.98 (out of 4) at MV1 to 3.23 at MV2 (MD=0.25, 95% CI 0.173 to 0.327, \( p \leq 0.001 \)).

Overall carers stated they felt that they had very good abilities to apply iCST key principles and skills related to the intervention with scores ranging from 3.76 to 3.96 at MV1 and improving between MV1 and MV2. These included ‘focusing on opinions rather than facts’ (MD=0.89, 95% CI 0.038 to 0.139, \( p \leq 0.001 \)), ‘developing ideas in a sensitive manner’ (MD=0.145, 95% CI 0.082 to 0.208, \( p \leq 0.001 \)), and ‘incorporating their relative’s personal interests in the activities’ (MD=0.153, 95% CI 0.078 to 0.229, \( p \leq 0.001 \)), and ‘adapting the sessions to accommodate their relative’s abilities’ (MD=0.089, 95% CI 0.017 to 0.160, \( p = 0.016 \)). At set up, 71% (122/173) carers anticipated they would need little or no support in delivering the intervention. Set up training, telephone support, and monitoring visits were well received by most carers, with 81% (114/141) ratings of ‘good’ or ‘excellent’.

The majority of carers (83%, 144/173) felt they would be able to engage in iCST with the person with dementia most, or all of the time. However, from the carer’s perspective there appeared to be no significant differences in the person with dementia’s level of engagement from MV1 to MV2 (MD=-0.016, 95% CI -0.067 to 0.034, \( p = 0.529 \)).
In terms of number of sessions completed, only 40% (72/180) of dyads allocated to iCST completed at least two sessions per week in line with the expected minimum for effectiveness, with 22% (39/180) completing no sessions at all.

**Exploratory analyses**

**Outcomes for people with dementia**

Twenty-two percent of the sample (39/180) in the iCST group did not complete any of the sessions, but 51% (91/180) were able to complete more than 30 sessions over 25 weeks. Forty percent completed two to three sessions per week. When the linear regression model was fitted, there was no relationship between the number of sessions attended and the primary outcomes at any time point. However, the total number of sessions was associated with a significant improvement in the quality of the caregiving relationship from the person with dementia’s viewpoint (QCPR total, \( p=0.003 \) QCPR Criticism, \( p=0.001 \)). This result was consistent for QCPR Total after regression analysis with imputed data. The imputation was not conducted for QCPR criticism at post-test as no data was missing (Table 4). At 13 week mid-point QCPR lower criticism had a significant association with higher number of sessions received (\( p=0.004 \)) (results shown in Table H in S1 Appendix).

**Outcomes for caregivers**
HADS depression scores showed a significant reduction in the iCST group post-test ($p=0.018$) for caregivers who had participated in a higher number of sessions (Table 4). This was supported by the imputation analysis ($p=0.013$).

**Serious Adverse Events (SAEs)**

Twenty-five SAEs occurred in the iCST group, and 26 in the TAU group of which 44 related to people with dementia and seven involved caregivers. The most frequent reported category of SAE was ‘hospitalisation’ (63%, 32/51) of which there were 16 instances in each group. There were more deaths in the TAU group (8/10) than the iCST group (2/10). Five SAEs categorized as ‘life threatening’ were recorded in total, three of which occurred in the iCST group, and four ‘medically significant’ SAEs occurred in the iCST group. For three people with dementia, two SAEs were reported, which were hospitalizations followed by death. We judged that none were definitely, probably, or possibly related to treatment received within the trial, either iCST or TAU.

**Discussion**

We undertook a pragmatic RCT to evaluate the impact of a programme of individual, home-based CST on cognition and QoL of people with dementia, and mental and physical health of caregivers. No significant differences were found between the iCST and TAU groups for the primary outcomes of: cognition and QoL for people with dementia, and mental and physical health for caregivers. iCST appeared to enhance the quality of the caregiving relationship from the person with dementia’s perspective. In addition, the caregivers in the intervention group benefitted in terms of improvements in QoL (EQ-5D). Analyses incorporating level of adherence to the
iCST programme (number of sessions completed) revealed that people with dementia who participated in more sessions were more likely to experience gains in the relationship with their caregiver at the primary end point of the study (26 weeks), and caregivers who completed more sessions had lower depressive symptoms. The EQ-5D demonstrated improvements in QoL for caregivers, but there was no difference in general health status (SF-12). The discrepancy in findings between these two measures may be related to inherent differences in the measures, or their sensitivity to change.

With a total of 356 participating pairs, to our knowledge this is the largest trial of a CST-based approach. The trial also represents an innovation in CST as previously the intervention had been delivered only in groups without caregivers. A potential limitation of this trial is the low levels of adherence to the intervention. Since less than half of the iCST group completed at least two sessions per week (72/180, 40%) and 22% (39/180) did not complete any sessions, the power of the study to identify significant differences in outcomes between the iCST and TAU groups may have been compromised.

Data from the development phase of the trial and qualitative data gathered from post trial interviews may yield insight into the reasons for low levels of adherence. The principal reason for non-adherence in the field-testing study was difficulty fitting iCST into a busy schedule.[51] In post trial interviews challenges that hindered adherence included; difficulty engaging the person in the activities which in some cases was due to the activities being too easy, poor health of the person with dementia, and having a negative outlook about the progressive nature of dementia which may have affected caregiver motivation to deliver the intervention.[60] It may be that the
intervention is simply not suitable for all and that there are particular characteristics of (a) the context in which the intervention is delivered (e.g. relationships, health, life events), (b) the person delivering the intervention (e.g. motivation, personality), and (c) the person receiving the intervention which act as mediators of successful engagement in, and adherence to the programme. More detailed investigation of these factors in order to discern their impact on adherence would be useful in future research.

We were able to standardize the training and support in order to maximize treatment adherence and fidelity. However, the quality of support and training provided may have varied between sites as it was delivered by a number of researchers with various levels of experience, skills, and qualifications. In terms of the extent to which the engagement strategies embedded into the trial (e.g. training, support, monitoring visits) were effective overall, data from the adherence questionnaires completed by caregivers at set up, MV1, and MV2 suggests the training and support provided by researchers was more than adequate, therefore these components may not account for poor adherence.

Caregiver ratings of confidence in delivery and knowledge of iCST was very high and significantly improved from set up to MV2. In addition, we observed significant improvements in caregivers’ ability to apply the key principles and use the skills and techniques related to iCST. Despite this, caregivers did not perceive any corresponding improvements in the person with dementia’s engagement. From a fidelity perspective, this data suggests that caregivers felt they were delivering the intervention as intended, and as they had been trained. However, a limitation of self-report methods such as questionnaires in lieu of more involved measures of fidelity
such as researcher observation of sessions, or audio/video recording is that it is
difficult to closely monitor exactly what was delivered. In contrast with the findings
from the training and monitoring visits, some caregivers who were interviewed post
trial reported that they did not feel skilled enough to deliver the intervention and that
the time between monitoring visits was too long. New paradigms in the design of
pragmatic trials outline how ‘implementation errors’ such as low treatment fidelity can
be avoided.[61]

Blinding to allocation appeared successful for the most part, with the majority of
researchers reporting dyads equally likely to be in the iCST or TAU groups. Dyads
were reminded not to disclose their allocation to visiting researchers. However, on
rare occasions they did share this information, or left iCST materials on show, which
were seen by the researcher during the 13 week mid-point or post-test assessment
visit. If researchers were unblinded at the 13 week mid-point, they were typically
advised not to conduct the post-test assessment if possible.

In terms of external validity, the intervention was tested in a wide diversity of urban
and rural areas across eight sites in the UK. Despite this, there was a lack of
variation in ethnicities of participants, which may affect scope for generalization of
results. Neither can we be sure the programme is suitable or acceptable across
different cultures with the current data we have. The group CST programme has
been successfully adapted for a wide range of cultures, with guidelines published to
assist this process,[62] thus iCST could be similarly tailored. Although like CST,
iCST was intended for people with mild to moderate dementia, most participants had
mild dementia and so it may be difficult to generalize the findings to people with
moderate dementia. A further limitation of the trial is the effect sizes for the
significant improvements observed in relationship quality from the person with dementia’s perspective and caregiver QoL are small. Consequently, the extent to which the findings translate to tangible clinical or real life benefits is hard to determine, particularly since investment of time and resources is necessary in order to deliver this intervention. However, there was lots of feedback from people to indicate that the iCST activities were meaningful, enjoyable, and stimulating suggesting that they may play a useful role as part of better care.[60]

This trial contributes further to the body of knowledge of dyadic psychosocial interventions and demonstrates the benefits of relationship-centered care. The findings support the use of mentally stimulating activities as a means of improving outcomes for people with dementia and their caregivers.[32,33] Whilst CST is categorized as an intervention for people with dementia, the involvement of a family caregiver in the delivery of iCST and the observed positive impact of the sessions on both the person and the caregiver categorize iCST as a multi-component intervention. iCST provides caregivers with training and the manual with guidance and key principles which may be psycho-educational. iCST may also have elements of a support intervention as caregivers were in regular telephone contact with researchers.

Improvements in the quality of the caregiving relationship were only demonstrated from the person with dementia’s perspective. Whilst caregiver QoL improved, the person with dementia’s QoL did not. This suggests that iCST may offer mutual, caregiver-specific, and patient-specific benefits. The sessions present opportunities
for joint activities between the person and the caregiver, which may contribute to the positive outcomes each experienced.

Hellstrom, Nolan & Lundh, found caregivers and people with dementia identified four activities they felt ‘sustained couplehood’: ‘talking things through’, ‘being appreciative and affectionate’, ‘making the best of things’, and ‘keeping the peace’. The iCST programme and key principles correspond to each of these needs, which may account for our findings. In terms of ‘talking things through’ iCST activities facilitate discussion and may reinforce positive patterns of communication, which may transfer to interactions outside the sessions. Affection and appreciation may be demonstrated in the supportive and fun atmosphere that sessions are intended to create. Pairs may view participating in activities together as a source of enjoyment related to ‘making the best of things’. Finally, the iCST key principle of ‘focusing on opinions rather than facts’ may contribute to ‘keeping the peace’ by reducing criticism and celebrating success rather than dwelling on failure.

Providing enjoyable activities for a person with dementia can improve caregiver well being,[63] thus adopting a facilitative role in iCST sessions may be the mechanism responsible for the observed improvements in caregiver QoL. This appears plausible given our finding that caregivers who delivered more iCST sessions had lower depressive symptoms.

The finding that the iCST programme did not significantly affect cognition contrasts with previous studies of group CST.[13,15,26-28] Furthermore, significant QoL benefits for people with dementia were not detected in this trial, despite being
consistently associated with both short and longer term programmes of group CST.[13,15,17] The social setting and additional stimulation from participating in a group context may account for the difference in outcomes between iCST and group CST. Woods and colleagues suggest that the reported quality of life benefits associated with CST are likely to be mediated by improvements in cognition.[21] Thus the lack of significant cognitive change experienced by people with dementia may account for our lack of findings on quality of life outcomes. Alternatively, an optimum ‘dose’ of iCST may be necessary to impact cognition. There is evidence to suggest that two sessions of group CST per week are associated with cognitive benefits, whereas once weekly sessions are not.[64] Given 22% (39/180) of the sample did not complete any iCST sessions, and adherence was generally low, people may not have received enough stimulation to benefit. The dyads who were either too busy or no longer wanted to participate amounted to just under 40% (18/46) of the total withdrawals, so in future studies it is possible that with alternative approaches to retention and closer monitoring, some of these may have been persuaded to stay in the trial.

Given some people with dementia and their family caregivers did not fully engage in iCST, the trial could be replicated with enhanced processes to support better adherence. In the development phase of this trial, delivery by paid caregivers was suggested as an alternative if family caregivers were not willing or able to deliver iCST, and field-testing with a sample of paid caregivers demonstrated this was feasible.[51] Therefore, future research should investigate how far adherence can be improved if the intervention is delivered by a healthcare professional or paid caregiver.
Although iCST does not appear to deliver clinical benefits for cognition and QoL for people with dementia, there was evidence of improvement in terms of the caregiving relationship from the person with dementia’s perspective. There was also evidence of improvement in caregivers’ QoL, and depressive symptoms for those who completed more sessions. From a clinical perspective, reduction in depressive symptoms and improved QoL of the caregiver by means of a low cost, non-drug intervention are worthwhile outcomes. The longer-term associated effect of reducing depression may be that caregivers remain better mentally, and perhaps physically (as a related consequence) for longer. This carries possible advantages such as prolonging their ability to provide care for the person with dementia, reduced instances of crises requiring intervention (e.g. emergency temporary hospitalization), and less burden on health and social care services as their health is maintained with less need for additional resources (e.g. medication, counseling, Cognitive Behavioral Therapy [CBT]). Enhancing the caregiving relationship through iCST may reduce the risk of presentation to services and deterioration of the person’s functioning which has been associated with conflict in the caregiving relationship.[10] In turn, risk of institutionalization may be reduced, or delayed which is important from a societal and cost perspective, as the cost of residential care is high.[65] This indicates that iCST may be introduced as a useful component of individually tailored home care packages which may also help maintain people with dementia in their home situation for longer.
<table>
<thead>
<tr>
<th>Abbreviations</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AD</td>
<td>Alzheimer's Disease</td>
</tr>
<tr>
<td>ADI</td>
<td>Alzheimer's Disease International</td>
</tr>
<tr>
<td>ANCOVA</td>
<td>Analysis of Co-Variance</td>
</tr>
<tr>
<td>ADAS-Cog</td>
<td>Alzheimer's Disease Assessment Scale - Cognitive Subscale</td>
</tr>
<tr>
<td>BL</td>
<td>Baseline</td>
</tr>
<tr>
<td>CD</td>
<td>Compact Disk</td>
</tr>
<tr>
<td>CMHT</td>
<td>Community Mental Health Team</td>
</tr>
<tr>
<td>BADLS</td>
<td>Bristol Activities of Daily Living Scale</td>
</tr>
<tr>
<td>CSRI</td>
<td>Client Service Receipt Inventory</td>
</tr>
<tr>
<td>CST</td>
<td>Cognitive Stimulation Therapy</td>
</tr>
<tr>
<td>DEMQoL</td>
<td>Dementia Quality of Life</td>
</tr>
<tr>
<td>DEMQoL-proxy</td>
<td>Dementia Quality of Life Proxy</td>
</tr>
<tr>
<td>DMEC</td>
<td>Data Monitoring Committee</td>
</tr>
<tr>
<td>DSM-IV</td>
<td>Diagnostic and Statistical Manual of Mental Disorders</td>
</tr>
<tr>
<td>DVD</td>
<td>Digital Versatile Disc</td>
</tr>
<tr>
<td>EQ-5D</td>
<td>European Quality of Life - 5 Dimensions</td>
</tr>
<tr>
<td>GDS</td>
<td>Geriatric Depression Scale</td>
</tr>
<tr>
<td>HADS</td>
<td>Hospital Anxiety and Depression Scale</td>
</tr>
<tr>
<td>HTA</td>
<td>Health Technology Assessment</td>
</tr>
<tr>
<td>iCST</td>
<td>Individual Cognitive Stimulation Therapy</td>
</tr>
<tr>
<td>ITT</td>
<td>Intention to Treat</td>
</tr>
<tr>
<td>LSE</td>
<td>London School of Economics</td>
</tr>
<tr>
<td>Maintenance CST</td>
<td>Maintenance Cognitive Stimulation Therapy</td>
</tr>
<tr>
<td>MD</td>
<td>Mean difference</td>
</tr>
</tbody>
</table>
MMSE  Mini Mental State Examination
MRC    Medical Research Council
NHS    National Health Service
NPI    Neuropsychiatric Inventory
NICE   National Institute for Health and Clinical Excellence
NIHR   National Institute of Health Research
NWORTH North Wales Organisation for Randomized Trials in Health
PSSRU  Personal Social Services Research Unit
QCPR   Quality of the Carer Patient Relationship
QoL    Quality of Life
QoL-AD Quality of Life Alzheimer’s Disease
RCT    Randomised controlled trial
RO     Reality Orientation
RS-14  Resilience Scale
SE     Standard Error
SF-12  Short Form-12 Health Survey
SMD    Standardised Mean Difference
TAU    Treatment As Usual
TSC    Trial Steering Committee
UCL    University College London
Acknowledgements

The authors thank the people with dementia and their family caregivers who took part in the iCST trial and development studies for their time and contributions. We also thank the iCST Trial Steering Committee (TSC) and Data Monitoring Committee (DMEC) members. The TSC was chaired by Professor James Lindesay and included Dr Vincent Kirchner, Dr Jan Oyebode, Rachel Thompson, Catherine Crombie, Alice Betts, Elayne Dunn, U Hla Htay, and Graham Stokes as independent members. The DMEC was chaired by Professor Jill Manthorpe, and included Jennifer Hellier (independent statistician), and David Prothero (caregiver). The views expressed in this article are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

iCST trial group

Trial investigators: London Professor Martin Orrell; Bangor Professor Bob Woods; Hull Professor Esme Moniz-Cook; Manchester Professor Alistair Burns, Dr. Iracema Leroi; Norfolk & Suffolk Dr. Hugo de Waal; Dorset Dr. Steve Simpson; Lincolnshire Dr. Steve Roberts; Devon Dr. Michael van Buren.

Trial coordinator: London Dr. Vasiliki Orgeta.

Study officers, research staff, experts and collaborators: London Dr Caroline Popham, Lauren Yates, Fara Hamidi, James Sinclair, Sharon Cooper, Tom Freeth, Linda Smith, Gillian Lasocki; Bangor Hannah Jelley, Julia Roberts, Dawn Jones, Claire Watkins, Kat Algar; Devon North Dr. Mark Harrison, Dr Arun Devasahayam, Paula Clark, Louise Wright, Sarah Bagwell, Amanda Skinner, Nathan Vernon; Devon South Leanne Timings, Joshua Williams, Gary Hodge, Natalie Portwine, Mike Visick, Wendy Colwell, Dr. Ruth Newman, Dr. San Sreenath; Dorset Caroline Coleman, Rebecca Weekes, Janet Craven; Hull Cathryn Hart, Saba Alam, Katie Gibson, Len
Stevens, Gavin Dawson, Irene Carr, Dr Rachel Whitehead, Dr Lucy Webster;

Lincolnshire Val Smith, Diane Brennan, Lizwi Nyathi; Manchester Dr Salman Karim,
Dr John Mulinga, Phillip Tinkler, Emma Oughton, Anita Davies, Kelly Birtwell, Lewis
Harpin, Marianne Hare, Janice Birt, Kerry Ward, Rowen Callaghan, Jenny
Maskell, Lesley Craven; Norfolk & Suffolk Dr Kathryn Sams, Juniper West, Sarah
Purdy, Bridget Veldhuis, Dr Gemma Ridel, Ralph Woodcock, Angelica Schiza, Kim
Clipsham, Moira Henderson, Wendy Dwornik, John Robinson.
References


57. Wagnild GM. The Resilience Scale: user's guide for the US English version of the Resilience Scale and the 14-item Resilience Scale (RS-14). Resilience Center; 2009.


Supporting information

Legends to S1 Appendix Text and Tables

S1 Appendix Text

Text A:
Text A: TIDier checklist describing the iCST intervention.
SD=Standard deviation

Text B:
Text B: Excerpt from Health Technologies Assessment (HTA) report (Orgeta et al., 2015) describing treatment as usual (TAU) in the iCST trial.

S1 Appendix Tables

Table A:
Table A: Themes of iCST sessions and order of appearance in the manual
iCST= Individual Cognitive Stimulation Therapy

Table B:
Table B: Characteristics of people with dementia and caregivers who completed the trial and those who did not

Table C:
Table C: Reasons for drop outs and withdrawals in the iCST and TAU groups * drop outs defined as failure to complete an assessment at mid-point. Withdrawals defined as ceasing to continue participating in the trial.
iCST= individual Cognitive Stimulation Therapy, TAU= Treatment as usual

Table D:
Table D: Researchers’ perceived group allocation at 13 week mid-point assessment (n=264)
iCST= individual Cognitive Stimulation Therapy, TAU= Treatment as usual
Table E:
Researchers’ perceived group allocation at 26 week post-test assessment ($n=255$)
iCST = individual Cognitive Stimulation Therapy, TAU = Treatment as usual

Table F:
Unadjusted means for each of the outcome measures for iCST and TAU at 13 week mid-point & 26 week post test.
iCST = individual Cognitive Stimulation Therapy group, SD = Standard deviation, [P] = Proxy rated measure, Mis. = missing data, TAU = Treatment as usual group, ADAS-Cog = Alzheimer’s Disease Assessment Scale-Cognitive, QoL-AD = Quality of Life Alzheimer’s Disease, DEMQoL = Dementia Quality of Life, NPI = Neuropsychiatric Inventory, GDS = Geriatric Depression Scale, QCPR = Quality of the Caregiving Relationship, MMSE = Mini-Mental State Examination, BADLS = Bristol Activities of Daily Living Scale, SF12 = Short Form Survey, HADS = Hospital Anxiety & Depression Scale, EQ-5D = EuroQoL, RS 14 = Resilience Scale

Table G:
Change from baseline for each of the outcome measures for iCST and TAU at 13 week mid-point & 26 week post test.
iCST = individual Cognitive Stimulation Therapy group, SD = Standard deviation, [P] = Proxy rated measure, TAU = Treatment as usual group, ADAS-Cog = Alzheimer’s Disease Assessment Scale-Cognitive, QoL-AD = Quality of Life Alzheimer’s Disease, DEMQoL = Dementia Quality of Life, NPI = Neuropsychiatric Inventory, GDS = Geriatric Depression Scale, QCPR = Quality of the Caregiving Relationship, MMSE = Mini-Mental State Examination, BADLS = Bristol Activities of Daily Living Scale, SF12 = Short Form Survey, HADS = Hospital Anxiety & Depression Scale, EQ-5D = EuroQoL, RS 14 = Resilience Scale

Table H:
Regression coefficient (and Standard Error [SE]) of the association between each person with dementia and caregiver outcome measure and the
number of sessions of iCST attended at 13 week mid-point after adjusting for the baseline outcome measures

* Significant difference
+ No missing data so imputed data rows left blank

iCST= individual Cognitive Stimulation Therapy group, SE= Standard error, [P]=Proxy rated measure, F = F statistic, TAU=Treatment as usual group, ADAS-Cog= Alzheimer’s Disease Assessment Scale-Cognitive, QoL-AD= Quality of Life Alzheimer’s Disease, DEMQoL=Dementia Quality of Life, NPI= Neuropsychiatric Inventory, GDS= Geriatric Depression Scale, QCPR= Quality of the Caregiving Relationship, MMSE= Mini-Mental State Examination, BADLS= Bristol Activities of Daily Living Scale, SF12=Short Form Survey, HADS=Hospital Anxiety & Depression Scale, EQ-5D= EuroQoL, RS 14= Resilience Scale
Fig 1: Participant flow through the trial. ‘Withdrawn’ indicates participants’ withdrawal from trial and all associated research activities. ‘Did not complete’ indicates participants who missed the 13 week mid-point assessment but returned for the 26 week post-test.
<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Person with dementia</th>
<th>Total (%)</th>
<th>iCST (%)</th>
<th>TAU (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(N=356)</td>
<td>(n=180)</td>
<td>(n=176)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>165/356 (46)</td>
<td>83/180 (46)</td>
<td>82/176 (47)</td>
<td></td>
</tr>
<tr>
<td>Ethnicity White</td>
<td>331/356 (93)</td>
<td>164/180 (91)</td>
<td>167/176 (95)</td>
<td></td>
</tr>
<tr>
<td>Marital Status: married/cohabiting/civil</td>
<td>252/356 (71)</td>
<td>125/180 (69)</td>
<td>127/176 (72)</td>
<td></td>
</tr>
<tr>
<td>partnership</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lives with spouse/partner</td>
<td>225/356 (63)</td>
<td>113/180 (63)</td>
<td>112/176 (64)</td>
<td></td>
</tr>
<tr>
<td>Highest level of education school</td>
<td>213/356 (60)</td>
<td>113/180 (63)</td>
<td>100/176 (57)</td>
<td></td>
</tr>
<tr>
<td>leaver (14-16 years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-cholinesterase inhibitors</td>
<td>270/356 (76)</td>
<td>136/180 (76)</td>
<td>134/176 (76)</td>
<td></td>
</tr>
</tbody>
</table>

| Characteristic                               | Caregiver            | Total (%) | iCST (%) | TAU (%) |
|                                              | (N=356)              | (n=180)   | (n=176)  |         |
| Female                                       | 261/356 (73)         | 135/180 (75) | 126/176 (72) |         |
| Ethnicity White                              | 329/356 (92)         | 164/180 (91) | 166/176 (94) |         |
| Marital Status: married/cohabiting/civil     | 297/356 (83)         | 149/180 (83) | 148/176 (84) |         |
| partnership                                  |                      |           |          |         |
| Lives with spouse/partner                    | 225/356 (63)         | 113/180 (63) | 112/176 (64) |         |
| Highest level of education school            | 213/356 (60)         | 113/180 (63) | 100/176 (57) |         |
| leaver (14-16 years)                         |                      |           |          |         |
| Anti-cholinesterase inhibitors               | 270/356 (76)         | 136/180 (76) | 134/176 (76) |         |

iCST = Individual Cognitive Stimulation Therapy, TAU = Treatment as Usual

Table 1: Baseline characteristics of person with dementia and caregiver
<table>
<thead>
<tr>
<th>Outcome Measure</th>
<th>iCST (N=134)</th>
<th>TAU (N=139)</th>
<th>MD</th>
<th>95% CI of MD</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADAS-Cog</td>
<td>20.03</td>
<td>20.58</td>
<td>-0.55</td>
<td>(-2.00, 0.90)</td>
<td>0.45</td>
</tr>
<tr>
<td>QoL-AD</td>
<td>37.90</td>
<td>37.92</td>
<td>-0.02</td>
<td>(-1.04, 1.00)</td>
<td>0.97</td>
</tr>
<tr>
<td>DEMQoL</td>
<td>94.45</td>
<td>94.14</td>
<td>0.31</td>
<td>(-1.62, 2.22)</td>
<td>0.79</td>
</tr>
<tr>
<td>NPI [P]</td>
<td>8.10</td>
<td>8.42</td>
<td>-0.32</td>
<td>(-2.78, 2.12)</td>
<td>0.79</td>
</tr>
<tr>
<td>GDS-15</td>
<td>3.29</td>
<td>3.31</td>
<td>-0.02</td>
<td>(-0.51, 0.47)</td>
<td>0.94</td>
</tr>
<tr>
<td>QCPR Total *</td>
<td>57.42</td>
<td>55.65</td>
<td>1.77</td>
<td>(0.26, 3.28)</td>
<td>0.02*</td>
</tr>
<tr>
<td>MMSE</td>
<td>19.63</td>
<td>20.10</td>
<td>-0.47</td>
<td>(-1.26, 0.30)</td>
<td>0.23</td>
</tr>
<tr>
<td>BADLS [P]</td>
<td>11.91</td>
<td>12.57</td>
<td>-0.66</td>
<td>(-2.07, 0.75)</td>
<td>0.36</td>
</tr>
<tr>
<td>QoL-AD [P]</td>
<td>32.45</td>
<td>32.00</td>
<td>0.45</td>
<td>(-0.71, 1.60)</td>
<td>0.45</td>
</tr>
<tr>
<td>DEMQoL [P]</td>
<td>99.67</td>
<td>97.94</td>
<td>1.73</td>
<td>(-0.61, 4.07)</td>
<td>0.15</td>
</tr>
<tr>
<td><strong>Caregiver</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SF12 Physical component</td>
<td>49.57</td>
<td>49.11</td>
<td>0.46</td>
<td>(-1.21, 2.13)</td>
<td>0.59</td>
</tr>
<tr>
<td>SF12 Mental component</td>
<td>48.44</td>
<td>48.31</td>
<td>0.13</td>
<td>(-1.65, 1.91)</td>
<td>0.89</td>
</tr>
<tr>
<td>HADS Anxiety</td>
<td>6.09</td>
<td>6.30</td>
<td>-0.21</td>
<td>(-0.94, 0.52)</td>
<td>0.57</td>
</tr>
<tr>
<td>HADS Depression</td>
<td>4.16</td>
<td>4.67</td>
<td>-0.51</td>
<td>(-1.09, 0.08)</td>
<td>0.09</td>
</tr>
<tr>
<td>EQ5D health state today</td>
<td>78.20</td>
<td>76.99</td>
<td>1.21</td>
<td>(-2.14, 4.57)</td>
<td>0.48</td>
</tr>
<tr>
<td>EQ5D calculated utility value*</td>
<td>0.82</td>
<td>0.76</td>
<td>0.06</td>
<td>(0.01, 0.10)</td>
<td>0.01*</td>
</tr>
<tr>
<td>RS 14</td>
<td>83.42</td>
<td>81.85</td>
<td>1.58</td>
<td>(-0.37, 3.52)</td>
<td>0.11</td>
</tr>
<tr>
<td>NPI Carer distress</td>
<td>3.13</td>
<td>3.22</td>
<td>-0.09</td>
<td>(-0.55, 0.37)</td>
<td>0.70</td>
</tr>
<tr>
<td>QCPR total</td>
<td>59.65</td>
<td>60.21</td>
<td>-0.56</td>
<td>(-1.93, 0.82)</td>
<td>0.43</td>
</tr>
</tbody>
</table>

iCST= individual Cognitive Stimulation Therapy group, CI = Confidence Interval, MD=Mean difference,[P]=Proxy rated measure, TAU=Treatment as usual group, ADAS-Cog=Alzheimer’s Disease Assessment Scale-Cognitive, QoL-AD=Quality of Life Alzheimer’s Disease, DEMQoL=Dementia Quality of Life, NPI=Neuropsychiatric Inventory, GDS=Geriatric Depression Scale, QCPR=Quality of the Caregiving Relationship, MMSE=Mini-Mental State Examination, BADLS=Bristol Activities of Daily Living Scale, SF12=Short Form Survey, HADS=Hospital Anxiety & Depression Scale, EQ-5D=EuroQoL, RS 14=Resilience Scale * Significant difference

Table 2: Outcome measures at 26 week post-test by iCST versus TAU: complete case analysis, adjusting for baseline outcome measures, marital status, center, age, and anticholinesterase inhibitors.

NB Complete case data is presented owing to little difference between this and imputed data results.
### Table 3: The means (± 95% CI) comparing the iCST and TAU for person with dementia outcome measures at 13 week mid-point after adjusting for marital status, center, age and anticholinesterase inhibitors. (Complete case data is presented due to little difference between this and imputed data results)

<table>
<thead>
<tr>
<th>13 week mid-point Person with dementia</th>
<th>Missing</th>
<th>iCST (N=142)</th>
<th>TAU (N=146)</th>
<th>MD</th>
<th>95% CI of MD</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADAS-Cog</td>
<td>10</td>
<td>22.00</td>
<td>21.71</td>
<td>0.29</td>
<td>(-1.10, 1.68)</td>
<td>0.68</td>
</tr>
<tr>
<td>QoL-AD</td>
<td>4</td>
<td>38.40</td>
<td>38.54</td>
<td>-0.14</td>
<td>(-1.12, 0.84)</td>
<td>0.78</td>
</tr>
<tr>
<td>DEMQoL</td>
<td>11</td>
<td>91.72</td>
<td>92.05</td>
<td>-0.33</td>
<td>(-2.31, 1.65)</td>
<td>0.74</td>
</tr>
<tr>
<td>NPI [P]</td>
<td>2</td>
<td>12.27</td>
<td>13.72</td>
<td>-1.45</td>
<td>(-3.68, 0.76)</td>
<td>0.20</td>
</tr>
<tr>
<td>GDS-15</td>
<td>12</td>
<td>3.27</td>
<td>3.36</td>
<td>-0.09</td>
<td>(-0.56, 0.38)</td>
<td>0.71</td>
</tr>
<tr>
<td>QCPR total</td>
<td>7</td>
<td>56.62</td>
<td>55.52</td>
<td>1.10</td>
<td>(-0.15, 2.35)</td>
<td>0.09</td>
</tr>
<tr>
<td>MMSE</td>
<td>3</td>
<td>20.32</td>
<td>20.16</td>
<td>0.16</td>
<td>(-0.60, 0.92)</td>
<td>0.69</td>
</tr>
<tr>
<td>BADLS [P]</td>
<td>1</td>
<td>12.73</td>
<td>12.93</td>
<td>-0.20</td>
<td>(-1.44, 1.04)</td>
<td>0.75</td>
</tr>
<tr>
<td>QoL-AD [P]</td>
<td>3</td>
<td>32.66</td>
<td>31.91</td>
<td>0.75</td>
<td>(-0.27, 1.77)</td>
<td>0.15</td>
</tr>
<tr>
<td>DEMQoL [P]</td>
<td>3</td>
<td>99.28</td>
<td>98.73</td>
<td>0.55</td>
<td>(-1.70, 2.80)</td>
<td>0.64</td>
</tr>
</tbody>
</table>

**Caregiver**

| SF12 Physical component              | 0       | 50.51        | 50.57       | -0.06  | (-1.45, 1.33)| 0.93    |
| SF12 Mental component                | 0       | 47.59        | 48.30       | -0.71  | (-2.34, 0.92)| 0.39    |
| HADS Anxiety                         | 1       | 10.47        | 10.31       | 0.16   | (-0.81, 1.15)| 0.74    |
| HADS Depression                      | 1       | 6.34         | 6.05        | 0.29   | (-0.35, 0.91)| 0.37    |
| EQ5D health state today              | 1       | 4.13         | 4.27        | -0.14  | (-0.67, 0.39)| 0.60    |
| EQ5D calculated utility value*       | 1       | 77.55        | 77.00       | 0.55   | (-2.59, 3.69)| 0.73    |
| RS 14                                | 1       | 0.81         | 0.79        | 0.02   | (-0.02, 0.06)| 0.19    |
| NPI Carer distress                   | 0       | 83.35        | 83.41       | -0.06  | (-1.63, 1.51)| 0.94    |
| QCPR total                           | 2       | 3.16         | 3.15        | 0.01   | (-0.43, 0.43)| 0.99    |

iCST= individual Cognitive Stimulation Therapy group, CI = Confidence Interval, MD=Mean difference,[P]=Proxy rated measure, TAU= Treatment as usual group, ADAS-Cog= Alzheimer’s Disease Assessment Scale-Cognitive, QoL-AD= Quality of Life Alzheimer’s Disease, DEMQoL=Dementia Quality of Life, NPI= Neuropsychiatric Inventory, GDS= Geriatric Depression Scale, QCPR= Quality of the Caregiving Relationship, MMSE= Mini-Mental State Examination, BADLS= Bristol Activities of Daily Living Scale, SF12=Short Form Survey, HADS=Hospital Anxiety & Depression Scale, EQ-5D=EuroQoL, RS 14= Resilience Scale * Significant difference at 5% level
### Observed data 26 weeks post-test

<table>
<thead>
<tr>
<th>Person with dementia</th>
<th>coefficient</th>
<th>95% CI</th>
<th>p value</th>
<th>Caregiver</th>
<th>coefficient</th>
<th>95% CI</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADAS-Cog</td>
<td>-0.013</td>
<td>(-0.040, 0.015)</td>
<td>.361</td>
<td>SF12 Physical component</td>
<td>.018</td>
<td>(-0.013, 0.049)</td>
<td>.275</td>
</tr>
<tr>
<td>QoL-AD</td>
<td>0.008</td>
<td>(-0.011, 0.027)</td>
<td>.402</td>
<td>SF12 Mental component +</td>
<td>.017</td>
<td>(-0.016, 0.050)</td>
<td>.338</td>
</tr>
<tr>
<td>DEMQoL</td>
<td>0.007</td>
<td>(-0.029, 0.044)</td>
<td>.691</td>
<td>HADS total</td>
<td>-0.020</td>
<td>(-0.042, 0.001)</td>
<td>.064</td>
</tr>
<tr>
<td>NPI total</td>
<td>-0.002</td>
<td>(-0.048, 0.044)</td>
<td>.927</td>
<td>HADS Anxiety</td>
<td>-0.007</td>
<td>(-0.021, 0.006)</td>
<td>.283</td>
</tr>
<tr>
<td>GDS 15</td>
<td>0.001</td>
<td>(-0.008, 0.011)</td>
<td>.815</td>
<td>HADS Depression *</td>
<td>-0.013</td>
<td>(-0.025, -0.003)</td>
<td>.018*</td>
</tr>
<tr>
<td>QCPR total *</td>
<td>0.043</td>
<td>(0.015, 0.071)</td>
<td>.003*</td>
<td>EQ5D health state today</td>
<td>0.020</td>
<td>(-0.043, 0.083)</td>
<td>.525</td>
</tr>
<tr>
<td>MMSE</td>
<td>0.006</td>
<td>(-0.009, 0.021)</td>
<td>.455</td>
<td>EQ5D calculated utility value</td>
<td>0.0007</td>
<td>(-0.000, 0.002)</td>
<td>.090</td>
</tr>
<tr>
<td>BADLS [P]</td>
<td>-0.015</td>
<td>(-0.041, 0.011)</td>
<td>.264</td>
<td>RS 14</td>
<td>0.023</td>
<td>(-0.013, 0.061)</td>
<td>.232</td>
</tr>
<tr>
<td>QoL-AD [P]</td>
<td>0.012</td>
<td>(-0.010, 0.034)</td>
<td>.269</td>
<td>NPI Carer distress</td>
<td>-0.005</td>
<td>(-0.014, 0.003)</td>
<td>.228</td>
</tr>
<tr>
<td>DEMQoL [P]</td>
<td>0.013</td>
<td>(-0.031, 0.058)</td>
<td>.558</td>
<td>QCPR</td>
<td>-0.006</td>
<td>(-0.032, 0.020)</td>
<td>.673</td>
</tr>
</tbody>
</table>

_iCST= individual Cognitive Stimulation Therapy group, CI = Confidence Interval, [P]=Proxy rated measure, SE= Standard Error, TAU=Treatment as usual group, ADAS-Cog= Alzheimer's Disease Assessment Scale-Cognitive, QoL-AD= Quality of Life Alzheimer’s Disease, DEMQoL=Dementia Quality of Life, NPI= Neuropsychiatric Inventory, GDS= Geriatric Depression Scale, QCPR= Quality of the Caregiving Relationship, MMSE= Mini-Mental State Examination, BADLS= Bristol Activities of Daily Living Scale, SF12= Short Form Survey, HADS=Hospital Anxiety & Depression Scale, EQ-5D= EuroQoL, RS 14= Resilience Scale * Significant difference

Table 4: Regression of outcome measures at 26 week post-test on the number of sessions of iCST attended, adjusting for baseline outcome measures, marital status, center, age, and anticholinesterase inhibitors.